PB1761: PRECLINICAL EVALUATION OF THE MENIN INHIBITOR ZIFTOMENIB IN PRIMARY AML SPECIMENS

類似資料

• Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with <i>MLL</i> rearrangement or <i>NPM1</i> mutation to venetoclax
  著者:: Johanna Rausch, 等
  出版事項: (2023-04-01)
• The MLL–Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML
  著者:: Milad Rasouli, 等
  出版事項: (2023-08-01)
• PB1885: PHASE 1 STUDY OF ZIFTOMENIB IN COMBINATION WITH VENETOCLAX, VENETOCLAX/AZACITIDINE, OR STANDARD INDUCTION (7 + 3) CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
  著者:: Amer M Zeidan, 等
  出版事項: (2023-08-01)
• S125: NON-GENETIC RESISTANCE TO MENIN INHIBITION IN AML IS REVERSIBLE BY PERTURBATION OF KAT6A
  著者:: Florian Perner, 等
  出版事項: (2023-08-01)
• Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1
  著者:: Warren Fiskus, 等
  出版事項: (2023-04-01)